Lantern Pharma Inc. (LTRN) stock
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.02 (-6.17%)
Close on Nov 17, 2026Market cap $4.67MP/E –Yield –
Lantern Pharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lantern Pharma's ebitda for the twelve months ending Sep 30, 2026 was -$16.48M. For fiscal 2025 it was -$17.96M. The highest annual figure on record is -$12.58M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.96M | – |
| FY2024 | Dec 31, 2024 | -$22.20M | – |
| FY2023 | Dec 31, 2023 | -$17.86M | – |
| FY2022 | Dec 31, 2022 | -$14.42M | – |
| FY2021 | Dec 31, 2021 | -$12.58M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$5.37M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.89M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.87M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$832.76K | – |
See a number that looks wrong?